Abstract:A 65-year-old woman presented with abdominal pain, weight loss, fatigue, and microcytic anemia. Esophagogastroduodenoscopy, until the second part of duodenum, was normal. Ultrasound and computed tomography demonstrated a solid mass in the distal duodenum. A repeat endoscopy confirmed an ulcerative, intraluminar mass in the third and fourth part of the duodenum. Segmental resection of the third and fourth portion of the duodenum was performed. Histology revealed an adenocarcinoma. On the 4 th postoperative day,… Show more
“…Moreover, it is responsible for only 1% of deaths due to gastrointestinal neoplasms [2, 4]. Approximately 30–50% of small intestinal adenocarcinomas occur in the duodenum [5].…”
This article focuses on the symptomatic and diagnostic problems of primary duodenal adenocarcinoma (PDA) by way of two case reports and a literature review. An 85-year-old woman with an adenocarcinoma in the 1st duodenal portion was offered palliative care. A 90-year-old woman with an adenocarcinoma in the 3rd duodenal portion was also offered palliative care. A unique finding in the two cases reported herein is that PDA did not cause stenosis and occlusion of the lumen. As no reports of PDA without stenosis have been published so far, these cases may add to our knowledge of PDA. The diagnosis of PDA is often delayed because its symptoms may be absent until the tumor has progressed, thus leading to a delay of several months. Patients typically present with a long history of variable and vague symptoms, and many are diagnosed with advanced disease. As regards clinical manifestations, abdominal pain is the most frequent symptom. The majority of these tumors are found to have infiltrated the duodenal wall at presentation, with many being unresectable due to local and distal invasion. Esophagogastroduodenoscopy and gastrointestinal barium radiography are the main diagnostic tests for PDA, detecting 88.6 and 83.3% of tumors, respectively. In some cases, ultrasonography or computed tomography are useful for detecting PDA and determining vascular invasion.
“…Moreover, it is responsible for only 1% of deaths due to gastrointestinal neoplasms [2, 4]. Approximately 30–50% of small intestinal adenocarcinomas occur in the duodenum [5].…”
This article focuses on the symptomatic and diagnostic problems of primary duodenal adenocarcinoma (PDA) by way of two case reports and a literature review. An 85-year-old woman with an adenocarcinoma in the 1st duodenal portion was offered palliative care. A 90-year-old woman with an adenocarcinoma in the 3rd duodenal portion was also offered palliative care. A unique finding in the two cases reported herein is that PDA did not cause stenosis and occlusion of the lumen. As no reports of PDA without stenosis have been published so far, these cases may add to our knowledge of PDA. The diagnosis of PDA is often delayed because its symptoms may be absent until the tumor has progressed, thus leading to a delay of several months. Patients typically present with a long history of variable and vague symptoms, and many are diagnosed with advanced disease. As regards clinical manifestations, abdominal pain is the most frequent symptom. The majority of these tumors are found to have infiltrated the duodenal wall at presentation, with many being unresectable due to local and distal invasion. Esophagogastroduodenoscopy and gastrointestinal barium radiography are the main diagnostic tests for PDA, detecting 88.6 and 83.3% of tumors, respectively. In some cases, ultrasonography or computed tomography are useful for detecting PDA and determining vascular invasion.
“…Malignant tumours of the duodenum are extremely uncommon, with primary cancers of the duodenum representing 0.3% of all gastrointestinal tumours 2 4. The most common malignancy to the duodenum is adenocarcinoma, which usually (a) arises in the second part of the duodenum, (b) develops in the seventh decade of life, and (c) causes abdominal pain, weight loss, nausea, vomiting, jaundice and/or haemorrhage 2 4 9. Incidence of adenocarcinoma in the small bowel is greatest in the duodenum (55%), followed by the jejunum (18%) and the ileum (13%) 3.…”
Section: Discussionmentioning
confidence: 99%
“…Benign duodenal neoplasms, such as Brunner's adenoma, are uncommon and found only in 0.3–4.6% of patients at oesophagogastroduodenoscopy (OGD) 1. Only 1% of all gastrointestinal malignancies are located in the small intestine, with duodenal adenocarcinomas representing 0.3% 2. Adenocarcinoma and carcinoid tumours are the most common histological type of primary malignant tumours of the small bowel 2.…”
Section: Introductionmentioning
confidence: 99%
“…Only 1% of all gastrointestinal malignancies are located in the small intestine, with duodenal adenocarcinomas representing 0.3% 2. Adenocarcinoma and carcinoid tumours are the most common histological type of primary malignant tumours of the small bowel 2. In the small bowel, adenocarcinoma most commonly arises in the duodenum (55%), followed by the jejunum (18%) and the ileum (13%) 3.…”
Endoscopic biopsies of duodenal polyp/mass lesions remain an uncommon specimen (0.01% in the authors' surgical pathology practice). Nevertheless, accurate identification of the exact pathology, even in 'poorly differentiated' high-grade carcinomas is advocated, as metastatic lesions will require specific treatment plans in conjunction with treatment of their primary tumour.
“…More distal levels of obstruction (e.g., 4th part of duodenum, proximal jejunum) may prove difficult to access with standard endoscopy equipment. 7 Of these options the placement of a SEMS is currently the most frequently undertaken. 6 SEMS insertion is most likely to be carried out endoscopically with fluoroscopic assistance.…”
A B S T R A C TThis review article presents the radiological options for management of malignant gastric outflow obstruction distal to the pylorus. We place these options in context with surgical and endoscopic alternatives and recommend their use, particularly in those institutions where endoscopic alternatives may not be readily available.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.